Ifinatamab deruxtecan by Daiichi Sankyo for Neuroendocrine Tumors: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Neuroendocrine Tumors.

IDWeek 2024: strategic approaches and challenges in mpox vaccination – Pharmaceutical Technology

At IDWeek 2024 in Los Angeles, California, recent updates on mpox (formerly known as monkeypox) were discussed. Significant advancements and remaining hurdles in vaccination strategies

November 12, 2024

Study reveals sharp surge in illicit fentanyl seizures

The number of illicit fentanyl seizures by law enforcement in the United States grew by more than 1,700 percent between 2017 and 2023, according to

May 13, 2024

Research offers hope for patients with lower lip sensory loss

The inferior alveolar nerve (IAN) is a branch of the trigeminal nerve and plays a vital role in providing sensation to the lower lip.

July 12, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.